OCS vs. LRMR, ANL, TRDA, TVTX, LXRX, SLRN, ATXS, VERV, CRBP, and KALV
Should you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Larimar Therapeutics (LRMR), Adlai Nortye (ANL), Entrada Therapeutics (TRDA), Travere Therapeutics (TVTX), Lexicon Pharmaceuticals (LXRX), Acelyrin (SLRN), Astria Therapeutics (ATXS), Verve Therapeutics (VERV), Corbus Pharmaceuticals (CRBP), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical preparations" industry.
Larimar Therapeutics (NASDAQ:LRMR) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, community ranking, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.
Larimar Therapeutics has higher earnings, but lower revenue than Oculis. Larimar Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.
Larimar Therapeutics presently has a consensus target price of $18.50, indicating a potential upside of 148.99%. Oculis has a consensus target price of $30.17, indicating a potential upside of 152.02%. Given Larimar Therapeutics' higher probable upside, analysts plainly believe Oculis is more favorable than Larimar Therapeutics.
Larimar Therapeutics has a net margin of 0.00% compared to Larimar Therapeutics' net margin of -6,712.02%. Oculis' return on equity of -35.69% beat Larimar Therapeutics' return on equity.
Larimar Therapeutics received 10 more outperform votes than Oculis when rated by MarketBeat users. However, 85.71% of users gave Oculis an outperform vote while only 60.87% of users gave Larimar Therapeutics an outperform vote.
91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 4.3% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Oculis had 2 more articles in the media than Larimar Therapeutics. MarketBeat recorded 15 mentions for Oculis and 13 mentions for Larimar Therapeutics. Oculis' average media sentiment score of 0.43 beat Larimar Therapeutics' score of 0.25 indicating that Larimar Therapeutics is being referred to more favorably in the media.
Larimar Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.
Summary
Larimar Therapeutics beats Oculis on 10 of the 16 factors compared between the two stocks.
Get Oculis News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
